MoonLake Immunotherapeutics(MLTX.US)

Last Updated 19:00:00 ET
longbridge loading
Company Encyclopedia
View More
name
MoonLake Immunotherapeutics
MLTX.US
MoonLake Immunotherapeutics, a clinical stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerland.
1.883 T
MLTX.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    OSE Immunotherapeutics Reports Increased Shares and Cash in Liquidity Account

    OSE Immunotherapeutics reported that its liquidity account held 40,086 shares and €413,431.33 in cash as of December 31, 2025. From July 1 to December 31, 2025, there were 926 buy-side executions totaling 169,447 shares for €993,349.58 and 1,019 sell-side executions totaling 157,153 shares for €948,518.44. This is an increase from June 30, 2025, when the account had 27,792 shares and €454,733.83 in cash.

    Reuters·
    US
    MLTX
    -2.57%
    Reuters·
    US
    MLTX
    -2.57%

    MoonLake Immunotherapeutics (MLTX) Is Down 7.4% After FDA Clears HS BLA Path Using Existing Trials

    MoonLake Immunotherapeutics (MLTX) shares fell 7.4% following FDA approval for a Biologics License Application for sonelokimab in hidradenitis suppurativa, utilizing existing trial data. The FDA's feedback allows the application to proceed without new trials, but emphasizes the need for safety data from VELA-2. Investors must consider the mixed Phase 3 results and ongoing losses, while regulatory uncertainties remain. Valuation estimates suggest the stock could be trading at a premium, with potential for an 11% increase from current levels. The analysis highlights risks and encourages diverse perspectives on investment decisions.

    Simplywall·
    US
    MLTX
    -2.57%
    Simplywall·
    US
    MLTX
    -2.57%

    U.S. stock market movement update: Abivax rises 22% leading the gains, Alpha Tech falls 13%, biotech sector active

    Overview of the US Stock Market Recently, the market has shown a clear characteristic of sector rotation, with stocks in the pharmaceutical and technology sectors performing particularly well. There seems to be a stronger preference for small-cap stocks and thematic stocks, driving significant gains in these stocks. The overall market rhythm is fast-paced, with large fluctuations, and short-term enthusiasm continues to rise, boosting investor sentiment. The stock with the largest movement, Abivax SA, leads the market with a 22.03% increase, with significant capital inflow, indicating strong investor confidence in its future development. The strong performance of this stock has also invigorated the overall activity in the pharmaceutical sector. Strong stocks: 1. Mereo Biopharma: up 19.03%, with significant capital inflow, and the market is full of expectations for its R&D progress. 2. 3 E Network Tech: up 18.06%, with continued enthusiasm in the technology sector and active participation from short-term capital. 3. Allogene Therapeutics: up 13.45%, with strong performance in the pharmaceutical sector attracting a lot of attention. 4. ZeZentalis Pharma: up 12.30%, with the market full of confidence in the potential of its innovative drugs. 5. Critical Metals: up 10.85%, with increased activity in the resource sector and significant capital inflow. 6. Regencell Bioscience: up 9.22%, with innovations in the biotechnology field attracting investors' attention

    Tracking Unusual Activity·
    US
    BEAT
    -3.37%
    US
    MLTX
    -2.57%
    Tracking Unusual Activity·
    US
    BEAT
    -3.37%
    US
    MLTX
    -2.57%

    U.S. Stock Movement Update: Abivax SA leads with a 22% increase, biotech stocks are active, Alpha Tech drops 11% attracting attention

    Market Overview of US Stocks in the Last Hour The US stock market has shown a clear sector rotation phenomenon in the last hour, with the pharmaceutical and biotechnology sectors performing particularly well and experiencing significant capital inflows. Small-cap stocks and thematic stocks have seen large fluctuations, with high short-term trading activity. Overall market sentiment is leaning positive, but some technology and financial stocks are under pressure, indicating a shift in capital preferences. The stock with the largest movement in the last hour, Abivax SA, surged by 22.03%, becoming the market focus. Driven by the pharmaceutical sector, the stock attracted short-term capital inflows and exhibited rapid fluctuations, leading to heightened market sentiment. Strong stocks: 1. Mereo Biopharma: up 19.64%, driven by strong performance in the biotechnology sector, with active short-term capital. 2. Allogene Therapeutics: up 14.62%, with significant capital inflows in the pharmaceutical sector pushing the stock price sharply higher. 3. 3 E Network Tech: up 13.18%, showing strong technical performance and attracting short-term capital. 4. ZeZentalis Pharma: up 12.83%, benefiting from the overall strength of the pharmaceutical sector. 5. Regencell Bioscience: up 9.41%, with the market optimistic about its technological prospects and noticeable capital inflows. 6. Critical Metals: up 9.32%, driven by active performance in the resource sector

    Tracking Unusual Activity·
    US
    BEAT
    -3.37%
    US
    MLTX
    -2.57%
    Tracking Unusual Activity·
    US
    BEAT
    -3.37%
    US
    MLTX
    -2.57%

    U.S. Stock Market Movement Update: The biotechnology sector strengthens, Abivax SA rises 21.95%, Alpha Tech falls 11.07%

    Overview of the US Stock Market In the past hour, the US stock market has shown a clear sector rotation characteristic, particularly with the pharmaceutical and biotechnology sectors performing prominently. Funds have flowed into small-cap stocks and thematic stocks, driving an increase in short-term enthusiasm. Market sentiment is leaning positive, with significant volatility, indicating strong investor interest in specific areas. The stock with the largest movement in the past hour, Abivax SA, leads the market with a 21.95% increase, demonstrating strong capital momentum. The overall activity in the pharmaceutical sector provides robust support, and the influx of short-term funds has accelerated its price movement. Strong stocks: 1. Mereo Biopharma: up 19.60%, the heat in the biotechnology sector continues to rise, attracting significant capital attention. 2. Allogene Therapeutics: up 16.96%, stands out in the pharmaceutical field with notable short-term capital inflow. 3. ZeZentalis Pharma: up 13.64%, market expectations for its future development are optimistic, driving the stock price up. 4. 3 E Network Tech: up 12.08%, the activity in the technology sector has propelled its stock price rapidly. 5. Regencell Bioscience: up 11.38%, the potential of innovative technology has attracted investors' attention. 6. flyExclusive: up 10.64%, signs of recovery in the aviation sector have boosted market confidence

    Tracking Unusual Activity·
    US
    BEAT
    -3.37%
    US
    MLTX
    -2.57%
    Tracking Unusual Activity·
    US
    BEAT
    -3.37%
    US
    MLTX
    -2.57%
    Posts
    View More

    The recent biotech stock market is really a tale of two extremes. CRSP and NTLA in hand are still struggling, chasing the dream of gene editing but completely missing the big surge of MLTX and ELVN, w...

    © 2026 Longbridge｜Disclaimer